secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001558370-24-012519
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phibro Q4 net sales up 7% to $273.2M; FY2025 guidance sees 10% adjusted EBITDA growth
--------------------------------------------------------------------------------

- Q4 GAAP net income of $0.8M ($0.02 EPS) vs $11.5M ($0.28 EPS) YoY; adjusted EPS $0.41 (+10%).
- Full-year net sales $1,017.7M (+4%); adjusted EBITDA $111.2M (-1%); adjusted EPS $1.19 (-1%).
- FY2025 guidance: net sales $1.04B-$1.09B, adjusted EBITDA $118M-$126M, adjusted EPS $1.22-$1.37.
- Free cash flow $46.4M; total debt $489.1M; cash & short-term investments $114.6M; gross leverage 4.4x.
- Guidance excludes proposed Zoetis MFA acquisition; company notes strength in Q4 Animal Health segment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024012519/0001558370-24-012519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000155837024012519/pahc-20240828x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer